Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of

bavituximab and docetaxel in patients with advanced breast cancer

within 14 days of study initiation.

-- Received regulatory approval to begin two additional Phase II

bavituximab combination therapy trials -- one in combination with

carboplatin and paclitaxel in patients with advanced breast cancer and

another in combination with carboplatin plus paclitaxel in patients

with non-small cell lung cancer (NSCLC). Both trials are preparing to

begin enrolling patients shortly.

-- A bavituximab cancer investigator presented data at a leading

scientific meeting on anti-angiogenic agents -- the 10th Annual

International Symposium on Anti-Angiogenic Agents (Angio 2008) --

highlighting the positive clinical experience to date with

bavituximab.

-- A preclinical study published in Clinical Cancer Research confirmed

bavituximab's ability to target tumor blood ves
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 WaferGen Biosystems, Inc. (OTC ... genetic analysis systems, today announced that it will ... innovative service for gene-expression profiling using its SmartChip(TM) ... provides the most comprehensive human microRNA panel of ... company,s SmartChip service offers customers the use of ...
(Date:12/16/2009)... turn microgears in suspended solution by swimming , ... ... -- Scientists at the U.S. Department of Energy’s (DOE) Argonne ... common bacteria can turn microgears when suspended in a solution, ... energy. , , ,“The gears are a million times more ...
(Date:12/16/2009)... 16 /PRNewswire/ -- Capitalizing ... sciences industry and an active venture capital market, ... State Teachers Retirement Fund, Indiana University, Purdue University, ... Foundation, and Credit Suisse today announced the establishment ... capital fund of funds. ,, Organized through BioCrossroads, ...
(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...
Breaking Biology Technology:WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8
... Sequential Profitable Quarter -- -- Conference Call ... BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... results for the three months and twelve months ended December ... 2007 sales of $33.5 million, up 118% year-over-year ...
... 28 Eisai Co.,Ltd. and its U.S. subsidiary ... States District Court for the District of New,Jersey ... Eisai,s motion for a,preliminary injunction in its patent ... Pharmaceuticals (collectively,"Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride,tablets)., ...
... N.J., March 28 Memory,Pharmaceuticals Corp. (Nasdaq: ... public accounting firm included an explanatory,paragraph in their ... recently filed Annual Report on Form 10-K for ... Company,s ability to continue as a going,concern. The ...
Other Biology Technology:Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification 2
(Date:12/16/2009)... 9 BIO-key International, Inc. (OTC ... biometric identification solutions, today announced that SC ... security publications, named BIO-key International the 2009 ... Control sub-category Biometrics. ,, (Logo: ... technology editor, SC Magazine, "Biometric providers have ...
(Date:12/15/2009)... 2009 Frost & Sullivan European Border Security ... Securite (Safran Group) for its innovative Automated ... company,s expertise in advanced biometric technology and ... products to end users. ,, (Logo: ... has been involved in delivering identification systems ...
(Date:12/15/2009)... just signed an agreement with the British Society for ... with the journal Biogerontology for an initial ... one member of the Biogerontology editorial board ... Springer will sponsor the society and provide society ... on www.springerlink.com . , Biogerontology offers ...
Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 1Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 2Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 3
... is a defensive, protective reaction. This ancestral and automatic ... potential predator. A new study published in Psychophysiology finds ... encountering a threat. The mere picture of an injured ... unpleasant images, the study's participants froze as their heart ...
... at Yale have identified a gene that regulates the ... according to a recent report in the journal Cell. ... zone of dead cells around an infection site that ... of Molecular, Cellular and Developmental Biology at Yale and ...
... new pan-genome , Ever since the genomics revolution ... numbers of genomes. Cataloging. Analyzing. Comparing. Public databases ... scientists at The Institute for Genomic Research (TIGR) ... the powerful tools of comparative genomics and mathematics, ...
Other Biology News:When in danger humans are similar to a deer in the headlights 2Researchers predict infinite genomes 2Researchers predict infinite genomes 3
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Component in MasterPure™ Purification Kits...
...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Biology Products: